Ultragenyx Faces Class Action Lawsuit Over Alleged Misleading Statements on Setrusumab Trials

Reuters

Feb 14

Ultragenyx Faces Class Action Lawsuit Over Alleged Misleading Statements on Setrusumab Trials

A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc., alleging that the company made materially false and misleading statements regarding the potential of its drug setrusumab, as well as the risks associated with its Phase III Orbit and Cosmic studies in patients with Osteogenesis Imperfecta. The suit claims that Ultragenyx assured investors of setrusumab's ability to decrease fracture rates, despite knowing that increased bone density observed in studies did not correlate with reduced fractures. It is alleged that these statements led investors to purchase shares at inflated prices, resulting in damages when the true information emerged. Investors who bought Ultragenyx stock between August 3, 2023 and December 26, 2025 may be eligible to participate in the litigation, with a deadline of April 6, 2026 to seek lead plaintiff status.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602132221NEWSFILECNPR____20260213_283848_1) on February 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611946190"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611946190\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611946190?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-14 11:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611946190","market":"fut","top_or_hot":-1,"title":"Ultragenyx Faces Class Action Lawsuit Over Alleged Misleading Statements on Setrusumab Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ultragenyx Faces Class Action Lawsuit Over Alleged Misleading Statements on Setrusumab Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against <a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical Inc</a>., alleging that the company made materially false and misleading statements regarding the potential of its drug setrusumab, as well as the risks associated with its Phase III Orbit and Cosmic studies in patients with Osteogenesis Imperfecta. The suit claims that Ultragenyx assured investors of setrusumab's ability to decrease fracture rates, despite knowing that increased bone density observed in studies did not correlate with reduced fractures. It is alleged that these statements led investors to purchase shares at inflated prices, resulting in damages when the true information emerged. Investors who bought Ultragenyx stock between August 3, 2023 and December 26, 2025 may be eligible to participate in the litigation, with a deadline of April 6, 2026 to seek lead plaintiff status.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602132221NEWSFILECNPR____20260213_283848_1) on February 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ultragenyx Faces Class Action Lawsuit Over Alleged Misleading Statements on Setrusumab Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltragenyx Faces Class Action Lawsuit Over Alleged Misleading Statements on Setrusumab Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-14 11:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ultragenyx Faces Class Action Lawsuit Over Alleged Misleading Statements on Setrusumab Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against <a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical Inc</a>., alleging that the company made materially false and misleading statements regarding the potential of its drug setrusumab, as well as the risks associated with its Phase III Orbit and Cosmic studies in patients with Osteogenesis Imperfecta. The suit claims that Ultragenyx assured investors of setrusumab's ability to decrease fracture rates, despite knowing that increased bone density observed in studies did not correlate with reduced fractures. It is alleged that these statements led investors to purchase shares at inflated prices, resulting in damages when the true information emerged. Investors who bought Ultragenyx stock between August 3, 2023 and December 26, 2025 may be eligible to participate in the litigation, with a deadline of April 6, 2026 to seek lead plaintiff status.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602132221NEWSFILECNPR____20260213_283848_1) on February 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RARE","symbol_name":"Ultragenyx Pharmaceutical Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260214:nNDLznZcf:1","article_id":"2611946190","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611946190","pubTimestamp":1771039317,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc., alleging that the company made materially false and misleading statements regarding the potential of its drug setrusumab, as well as the risks associated with its Phase III Orbit and Cosmic studies in patients with Osteogenesis Imperfecta. The suit claims that Ultragenyx assured investors of setrusumab's ability to decrease fracture rates, despite knowing that increased bone density observed in studies did not correlate with reduced fractures. It is alleged that these statements led investors to purchase shares at inflated prices, resulting in damages when the true information emerged. Investors who bought Ultragenyx stock between August 3, 2023 and December 26, 2025 may be eligible to participate in the litigation, with a deadline of April 6, 2026 to seek lead plaintiff status.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RARE":"Ultragenyx Pharmaceutical Inc","BK4139":"生物科技"},"translate_title":"Ultragenyx因涉嫌对Setrusumab试验的误导性陈述而面临集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RARE":0.9},"content_text":"Ultragenyx Faces Class Action Lawsuit Over Alleged Misleading Statements on Setrusumab Trials\n    \n\n        A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc., alleging that the company made materially false and misleading statements regarding the potential of its drug setrusumab, as well as the risks associated with its Phase III Orbit and Cosmic studies in patients with Osteogenesis Imperfecta. The suit claims that Ultragenyx assured investors of setrusumab's ability to decrease fracture rates, despite knowing that increased bone density observed in studies did not correlate with reduced fractures. It is alleged that these statements led investors to purchase shares at inflated prices, resulting in damages when the true information emerged. Investors who bought Ultragenyx stock between August 3, 2023 and December 26, 2025 may be eligible to participate in the litigation, with a deadline of April 6, 2026 to seek lead plaintiff status.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602132221NEWSFILECNPR____20260213_283848_1) on February 14, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}